EVALUATION OF INDETERMINATE C22-3 REACTIVITY IN VOLUNTEER BLOOD-DONORS

被引:50
作者
TOBLER, LH
BUSCH, MP
WILBER, J
DINELLO, R
QUAN, S
POLITO, A
KOCHESKY, R
BAHL, C
NELLES, M
LEE, SR
机构
[1] UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143
[2] CHIRON CORP,EMERYVILLE,CA
[3] ORTHO PHARMACEUT CORP,DIAGNOST SYST,RARITAN,NJ
关键词
D O I
10.1046/j.1537-2995.1994.34294143940.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Approximately 25 percent of blood donor sera that are repeatably reactive for hepatitis C virus (HCV) on second-generation enzyme immunoassay (EIA 2.0) are indeterminate on second-generation recombinant immunoblot assay (RIBA 2.0), and over 76 percent of these results are due to single reactivity to the HCV recombinant antigen c22-3. Study Design and Methods: Data are presented on 46 volunteer allogeneic blood donors who were reactive on EIA 2.0 and c22-3 indeterminate in RIBA 2.0. Index and follow-up samples were evaluated by using a panel of five synthetic peptide EIAs, a prototype strip immunoblot assay that uses synthetic peptides in addition to recombinant protein (RIBA 3.0), and polymerase chain reaction (PCR) for HCV RNA. Results: All 46 donations had normal alanine aminotransferase values; only 2 (4.3%) reacted for antibody to hepatitis B core antigen. With a panel of 12 synthetic peptides spanning the entire sequence of the c22-3 recombinant antigen, 33 Plasmas (72%) reacted to one peptide or none, including 19 plasmas with reactivity restricted entirely to the N-terminal peptide (1-15 amino acids) of c22-3. With RIBA 3.0, 28 donations (61%) were nonreactive, including 25 that reacted with one peptide or none in EIA. Of these 25 plasmas, 18 reacted with the N-terminal sequence only. All 46 index donations were tested by PCR; the single PCR-positive unit reacted with four HCV peptides, was positive by RIBA 3.0, and reacted for antibody to hepatitis B core antigen. Twenty-six index donors were successfully recalled 3 to 7 months after their index donation. None seroconverted to positivity in RIBA 2.0, 1 was nonreactive, and 25 remained positive for c22-3 only. The restricted epitope reactivity in peptide EIA and RIBA 3.0 was maintained over time in all cases. All 26 of the follow-up samples tested negative by PCR. Conclusion: On the basis of,the restricted peptide reactivity and PCR negativity of index and follow-up samples, it is concluded that the majority of c22-3 RIBA 2.0-indeterminate results are due to nonspecific cross reactivity to restricted (principally, N-terminal) regions of HCV core antigen.
引用
收藏
页码:130 / 134
页数:5
相关论文
共 7 条
[1]   CLINICAL IMPORTANCE OF HCV CONFIRMATORY TESTING IN BLOOD-DONORS [J].
ALLAIN, JP ;
RANKIN, A ;
KUHNS, MC ;
MCNAMARA, A .
LANCET, 1992, 339 (8802) :1171-1172
[2]   HCV CONFIRMATORY TESTING OF BLOOD-DONORS [J].
BOUDART, D ;
LUCAS, JC ;
ADJOU, C ;
MULLER, JY .
LANCET, 1992, 339 (8789) :372-372
[3]   A PATTERN OF 5-1-1 AND C100-3 ONLY ON HEPATITIS-C VIRUS (HCV) RECOMBINANT IMMUNOBLOT ASSAY DOES NOT REFLECT HCV INFECTION IN BLOOD-DONORS [J].
BUSCH, MP ;
TOBLER, L ;
QUAN, S ;
WILBER, JC ;
JOHNSON, P ;
POLITO, A ;
STEANE, E ;
ZOLA, A ;
BAHL, C ;
NELLES, M ;
LEE, SR .
TRANSFUSION, 1993, 33 (01) :84-88
[4]   EVALUATION OF ANTI-HCV CAPSID INDETERMINATE SERUM SAMPLES [J].
CLAEYS, H ;
VOLKAERTS, A ;
VERHAERT, H ;
DEBEENHOUWER, H ;
VERMYLEN, C .
LANCET, 1992, 340 (8813) :249-249
[5]   HCV CONFIRMATORY TESTING OF BLOOD-DONORS [J].
FOLLETT, EAC ;
DOW, BC ;
MCOMISH, F ;
YAP, PL ;
HUGHES, W ;
MITCHELL, R ;
SIMMONDS, P .
LANCET, 1991, 338 (8773) :1024-1024
[6]   AVOIDING FALSE POSITIVES WITH PCR [J].
KWOK, S ;
HIGUCHI, R .
NATURE, 1989, 339 (6221) :237-238
[7]  
LI X, 1992, HEPATOLOGY, V16, pA73